16381-46-7

Usage

Uses

Used in Pharmaceutical Industry:
5-Fluoro-3-methyl-1H-indole-2-carboxylic acid is used as a building block for the synthesis of pharmaceuticals, leveraging its structural features and reactivity to contribute to the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-Fluoro-3-methyl-1H-indole-2-carboxylic acid is utilized as a key intermediate for the preparation of complex molecules with potential biological activities, facilitating the discovery of novel compounds with therapeutic applications.
Used in Drug Design:
5-Fluoro-3-methyl-1H-indole-2-carboxylic acid is employed as a component in drug design, where its unique structural elements can be incorporated into the molecular frameworks of new drug candidates to enhance their pharmacological properties and target specific biological pathways.
Used in Organic Synthesis:
As a reagent or intermediate in organic synthesis, 5-Fluoro-3-methyl-1H-indole-2-carboxylic acid is used for the preparation of a variety of complex organic molecules, expanding the scope of chemical compounds available for further research and application in various industries.

InChI:InChI=1/C10H8FNO2/c1-5-7-4-6(11)2-3-8(7)12-9(5)10(13)14/h2-4,12H,1H3,(H,13,14)

Upstream product

• 16382-19-7 ethyl 5-fluoro-3-methyl-1H-indole-2-carboxylate 

Downstream Products

• 392-13-2 5-fluoro-3-methyl-1H-indole 

Relevant academic research and scientific papers

Mutational biosynthesis to generate novel analogs of nosiheptide featuring a fluorinated indolic acid moiety

Nosiheptide (NOS) is a member of bicyclic thiopeptides possessing a biologically important indolic acid (IA) moiety appended onto the family-characteristic core system. The IA formation relies primarily on NosL, a radical S-adenosylmethionine (SAM) protein that catalyzes a complex rearrangement of the carbon side chain ofl-tryptophan, leading to the generation of 3-methyl-2-indolic acid (MIA). Here, we establish an efficient mutational biosynthesis strategy for the structural expansion of the side-ring system of NOS. ThenosL-deficient mutantStreptomyces actuosusSL4005 complemented by chemically feeding 6-fluoro-MIA is capable of accumulating two new products. The target product 6′-fluoro-NOS contains an additional fluorine atom at C6 of the IA moiety, in contrast with an unexpected product 6′-fluoro-NOSint that features an open side ring and a bis-dehydroalanine (Dha) tail. The newly obtained 6′-fluoro-NOS displayed equivalent or slightly reduced activities against the tested drug-resistant pathogens compared with NOS, but dramatically decreased water solubility compared with NOS. Our results indicate that the modification of the IA moiety of NOS not only affects its biological activity but also affects its activity which will be key considerations for further modification.

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Phenylaminopropanol derivatives and methods of their use

The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Phenylaminopropanol derivatives and methods of their use

The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.